The World Health Organization has added GLP-1 receptor agonists, such as Ozempic and Mounjaro, to its Essential Medicines List, highlighting their proven role in managing type 2 diabetes with complications like heart or kidney disease. This move aims to improve affordability, and expand access globally, especially in low and middle-income nations, while discouraging cosmetic weight-loss use.